Alissa Dei Cas
Medizinische Onkologie und Hämatologie · Dept. I
Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.
Oct 31, 2024
Clinical Studies - Oct 31, 2024 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Dei Cas Alissa, Quinter Janine
SAKK 66/22 - Invincible 4 SAKK
Oct 17, 2024Protocol SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An openlabel randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
Clinical Studies - Oct 17, 2024 - Dec 31, 2029
Ongoing
Project leader: Jörger Markus
Members: Dei Cas Alissa, Müller Fiona
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Oct 7, 2024
Clinical Studies - Oct 7, 2024 - Dec 31, 2099
Ongoing
Project leader: Schittenhelm Marcus
Members: Dei Cas Alissa, Quinter Janine
MS201924_0002
Sep 30, 2024An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD) p...
Clinical Studies - Sep 30, 2024 - Sep 30, 2028
Ongoing
Project leader: Huober Jens
Members: Dei Cas Alissa, Müller Fiona
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Nov 17, 2023Forscher suchen nach einer besseren Möglichkeit, fortgeschrittenes Pleuramesotheliom zu behandeln. Pleuramesotheliom ist eine Krebsart, die die Lungenschleimhaut befällt. Fortgeschritten bedeutet in der Regel, dass der Krebs nicht operativ behandelt...
Clinical Studies - Nov 17, 2023 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Dei Cas Alissa, Quinter Janine
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IberDd)VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) (EXCALIBER-RRMM)
Aug 2, 2022Ziel dieser Studie ist es, die Wirksamkeit eines neuen Prüfpräparats, Iberdomid (CC-220) in Kombination mit Daratumumab und Dexamethason (IberDd) zur Behandlung des rezidivierten oder refraktären Mul-tiplen Myeloms mit der von Daratumumab, Borte-zomi...
Clinical Studies - Aug 2, 2022 - Nov 14, 2024
Automatically Closed
Project leader: Lehmann Thomas
Members: Dei Cas Alissa, Müller Fiona